Bolt Biotherapeutics, Inc. engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors.
| Market Cap | 64.282 Million | Shares Outstanding | 37.813 Million | Avg 30-day Volume | 210.441 Thousand |
| P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -2.17 |
| Price to Revenue | 7.7693 | Debt to Equity | 0.0 | EBITDA | -84.218 Million |
| Price to Book Value | 0.3322 | Operating Margin | -1258.677 | Enterprise Value | -118.584 Million |
| Current Ratio | 8.098 | EPS Growth | 0.121 | Quick Ratio | 7.776 |
| 1 Yr BETA | 0.5945 | 52-week High/Low | 2.72 / 1.18 | Profit Margin | -1207.3569 |
| Operating Cash Flow Growth | -16.6119 | Altman Z-Score | -2.125 | Free Cash Flow to Firm | -62.943 Million |
| Earnings Report | 2023-08-09 |
Please sign in first
none
none
none
| Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
|---|---|---|---|---|
|
YONEHIRO GRANT CHIEF BUSINESS OFFICER |
|
0 | 2023-02-27 | 2 |
|
SCHATZMAN RANDALL C CHIEF EXECUTIVE OFFICER |
|
0 | 2023-02-27 | 2 |
|
QUINN WILLIAM P. CHIEF FINANCIAL OFFICER |
|
0 | 2023-02-27 | 2 |
|
PEREZ EDITH A. CHIEF MEDICAL OFFICER |
|
0 | 2023-02-27 | 2 |
|
25,000 | 2022-12-14 | 2 | |
|
25,000 | 2022-12-14 | 2 | |
|
0 | 2022-12-14 | 2 | |
|
3,703,991 | 2022-07-13 | 1 | |
|
25,000 | 2022-06-10 | 1 | |
|
25,000 | 2022-06-10 | 1 | |
|
25,000 | 2022-06-10 | 1 | |
|
25,000 | 2022-06-10 | 1 | |
|
25,000 | 2022-06-10 | 1 | |
|
25,000 | 2022-06-10 | 1 | |
|
DORNAN DAVID CHIEF SCIENTIFIC OFFICER |
|
210,000 | 2022-02-18 | 0 |
|
SOFINNOVA VENTURE PARTNERS X, L.P. |
|
No longer subject to file | 2021-02-09 | 0 |
|
3,871,291 | 2021-02-09 | 0 | |
|
2,200 | 2021-02-09 | 0 | |
|
42,855 | 2021-02-04 | 0 | |
|
SOTO RAYMOND M CEO, CHAIRMAN |
|
211,559 | 2014-05-09 | 0 |
|
27,775 | 2013-11-26 | 0 | |
|
HEDGER MICHAEL C COO, PRESIDENT |
|
69,739 | 2012-11-21 | 0 |
|
ESPESO JOSEPH SENIOR VP FINANCE |
|
28,692 | 2011-12-20 | 0 |
|
13,800 | 2011-11-30 | 0 | |
|
1,300 | 2011-11-25 | 0 | |
|
10,824 | 2008-10-27 | 0 |
| Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No current insider transactions | ||||||||||||||||
* -
| Code | Definition |
|---|---|
| A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
| C | Conversion of derivative security |
| D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
| E | Expiration of short derivative position |
| F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
| G | Bona fide gift |
| H | Expiration (or cancellation) of long derivative position with value received |
| I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
| J | Other acquisition or disposition |
| L | Small acquisition under Rule 16a-6 |
| M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
| O | Exercise of out-of-the-money derivative security |
| P | Open market or private purchase of non-derivative or derivative security |
| S | Open market or private sale of non-derivative or derivative security |
| U | Disposition pursuant to a tender of shares in a change of control transaction |
| W | Acquisition or disposition by will or the laws of descent and distribution |
| X | Exercise of in-the-money or at-the-money derivative security |
| Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
| Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
|---|---|---|---|---|
| BOLT BIOTHERAPEUTICS INC BOLT | 2023-06-02 12:45:03 UTC | 2.8966 | 2.1734 | 1800000 |
| BOLT BIOTHERAPEUTICS INC BOLT | 2023-06-01 22:15:04 UTC | 2.9577 | 2.1123 | 1800000 |
| BOLT BIOTHERAPEUTICS INC BOLT | 2023-06-01 21:45:04 UTC | 2.9577 | 2.1123 | 1800000 |
| BOLT BIOTHERAPEUTICS INC BOLT | 2023-06-01 21:15:05 UTC | 2.9577 | 2.1123 | 1800000 |
| BOLT BIOTHERAPEUTICS INC BOLT | 2023-06-01 20:45:03 UTC | 2.9577 | 2.1123 | 1800000 |
| BOLT BIOTHERAPEUTICS INC BOLT | 2023-06-01 20:15:04 UTC | 2.9577 | 2.1123 | 1800000 |
| BOLT BIOTHERAPEUTICS INC BOLT | 2023-06-01 19:45:03 UTC | 2.9577 | 2.1123 | 1800000 |
| BOLT BIOTHERAPEUTICS INC BOLT | 2023-06-01 19:15:04 UTC | 2.9577 | 2.1123 | 1800000 |
| BOLT BIOTHERAPEUTICS INC BOLT | 2023-06-01 18:45:03 UTC | 2.9577 | 2.1123 | 1800000 |
| BOLT BIOTHERAPEUTICS INC BOLT | 2023-06-01 18:15:04 UTC | 2.9577 | 2.1123 | 1800000 |
| BOLT BIOTHERAPEUTICS INC BOLT | 2023-06-01 17:45:04 UTC | 2.9577 | 2.1123 | 1800000 |
| BOLT BIOTHERAPEUTICS INC BOLT | 2023-06-01 17:15:04 UTC | 2.9577 | 2.1123 | 1800000 |
| BOLT BIOTHERAPEUTICS INC BOLT | 2023-06-01 16:45:04 UTC | 2.9477 | 2.1123 | 1800000 |
| BOLT BIOTHERAPEUTICS INC BOLT | 2023-06-01 16:15:04 UTC | 2.9477 | 2.1123 | 1800000 |
| BOLT BIOTHERAPEUTICS INC BOLT | 2023-06-01 15:45:03 UTC | 2.9477 | 2.1123 | 1800000 |
| BOLT BIOTHERAPEUTICS INC BOLT | 2023-06-01 15:15:04 UTC | 2.9477 | 2.1123 | 1800000 |
| BOLT BIOTHERAPEUTICS INC BOLT | 2023-06-01 14:45:04 UTC | 2.9477 | 2.1123 | 1700000 |
| BOLT BIOTHERAPEUTICS INC BOLT | 2023-06-01 14:15:04 UTC | 2.9477 | 2.1123 | 1800000 |
| BOLT BIOTHERAPEUTICS INC BOLT | 2023-06-01 13:45:04 UTC | 2.891 | 2.169 | 1800000 |
| BOLT BIOTHERAPEUTICS INC BOLT | 2023-06-01 13:15:04 UTC | 2.891 | 2.169 | 1800000 |
| Holder | Issuer | Net Short Position | Position Date | Origin |
|---|
